Treatment of multidrug resistant (MDR1) murine leukemia with P-glycoprotein substrates accelerates the course of the disease

Jin-Ming Yang, Guang Yu Yang, Daniel J. Medina, Andrew D. Vassil, Jie Liao, William N. Hait

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The prognosis of patients with tumors expressing P-glycoprotein (P-gp), the MDR1 gene product, is generally poor. It is assumed that this is due to decreased tumor responsiveness that results from decreased drug accumulation. We observed that treatment of animals bearing MDR1-transfected leukemic cells with P-gp substrates (i.e., drugs that are transported by P-gp) significantly worsened host survival compared to treatment with vehicle or non-P-gp substrates. This effect was seen with cancer chemotherapeutic agents (paclitaxel and vincristine) and with the MDR modulator, trans-flupenthixol. To determine the mechanism(s) underlying this observation, we studied alterations in pharmacokinetics, pharmacodynamics, and metastasis. We found that the drug-induced acceleration of disease was associated with increased metastases. P-gp(+) cells treated with P-gp substrates demonstrated several pro-metastatic features, including membrane ruffling and invasion through a hepatocyte monolayer. These results suggest that the treatment of MDR tumors with P-gp substrates may produce changes in malignant behavior that could adversely affect therapeutic outcomes.

Original languageEnglish (US)
Pages (from-to)167-173
Number of pages7
JournalBiochemical and Biophysical Research Communications
Volume266
Issue number1
DOIs
StatePublished - Dec 9 1999

Fingerprint

P-Glycoprotein
Leukemia
Substrates
Tumors
Neoplasms
Bearings (structural)
Therapeutics
Flupenthixol
Pharmacodynamics
Pharmaceutical Preparations
Neoplasm Metastasis
Pharmacokinetics
Vincristine
Paclitaxel
Modulators
Hepatocytes
Monolayers
Glycoproteins
Animals
Genes

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Yang, Jin-Ming ; Yang, Guang Yu ; Medina, Daniel J. ; Vassil, Andrew D. ; Liao, Jie ; Hait, William N. / Treatment of multidrug resistant (MDR1) murine leukemia with P-glycoprotein substrates accelerates the course of the disease. In: Biochemical and Biophysical Research Communications. 1999 ; Vol. 266, No. 1. pp. 167-173.
@article{ccf9fd4fad8c4ff6948ac14e97e30637,
title = "Treatment of multidrug resistant (MDR1) murine leukemia with P-glycoprotein substrates accelerates the course of the disease",
abstract = "The prognosis of patients with tumors expressing P-glycoprotein (P-gp), the MDR1 gene product, is generally poor. It is assumed that this is due to decreased tumor responsiveness that results from decreased drug accumulation. We observed that treatment of animals bearing MDR1-transfected leukemic cells with P-gp substrates (i.e., drugs that are transported by P-gp) significantly worsened host survival compared to treatment with vehicle or non-P-gp substrates. This effect was seen with cancer chemotherapeutic agents (paclitaxel and vincristine) and with the MDR modulator, trans-flupenthixol. To determine the mechanism(s) underlying this observation, we studied alterations in pharmacokinetics, pharmacodynamics, and metastasis. We found that the drug-induced acceleration of disease was associated with increased metastases. P-gp(+) cells treated with P-gp substrates demonstrated several pro-metastatic features, including membrane ruffling and invasion through a hepatocyte monolayer. These results suggest that the treatment of MDR tumors with P-gp substrates may produce changes in malignant behavior that could adversely affect therapeutic outcomes.",
author = "Jin-Ming Yang and Yang, {Guang Yu} and Medina, {Daniel J.} and Vassil, {Andrew D.} and Jie Liao and Hait, {William N.}",
year = "1999",
month = "12",
day = "9",
doi = "10.1006/bbrc.1999.1757",
language = "English (US)",
volume = "266",
pages = "167--173",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "1",

}

Treatment of multidrug resistant (MDR1) murine leukemia with P-glycoprotein substrates accelerates the course of the disease. / Yang, Jin-Ming; Yang, Guang Yu; Medina, Daniel J.; Vassil, Andrew D.; Liao, Jie; Hait, William N.

In: Biochemical and Biophysical Research Communications, Vol. 266, No. 1, 09.12.1999, p. 167-173.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment of multidrug resistant (MDR1) murine leukemia with P-glycoprotein substrates accelerates the course of the disease

AU - Yang, Jin-Ming

AU - Yang, Guang Yu

AU - Medina, Daniel J.

AU - Vassil, Andrew D.

AU - Liao, Jie

AU - Hait, William N.

PY - 1999/12/9

Y1 - 1999/12/9

N2 - The prognosis of patients with tumors expressing P-glycoprotein (P-gp), the MDR1 gene product, is generally poor. It is assumed that this is due to decreased tumor responsiveness that results from decreased drug accumulation. We observed that treatment of animals bearing MDR1-transfected leukemic cells with P-gp substrates (i.e., drugs that are transported by P-gp) significantly worsened host survival compared to treatment with vehicle or non-P-gp substrates. This effect was seen with cancer chemotherapeutic agents (paclitaxel and vincristine) and with the MDR modulator, trans-flupenthixol. To determine the mechanism(s) underlying this observation, we studied alterations in pharmacokinetics, pharmacodynamics, and metastasis. We found that the drug-induced acceleration of disease was associated with increased metastases. P-gp(+) cells treated with P-gp substrates demonstrated several pro-metastatic features, including membrane ruffling and invasion through a hepatocyte monolayer. These results suggest that the treatment of MDR tumors with P-gp substrates may produce changes in malignant behavior that could adversely affect therapeutic outcomes.

AB - The prognosis of patients with tumors expressing P-glycoprotein (P-gp), the MDR1 gene product, is generally poor. It is assumed that this is due to decreased tumor responsiveness that results from decreased drug accumulation. We observed that treatment of animals bearing MDR1-transfected leukemic cells with P-gp substrates (i.e., drugs that are transported by P-gp) significantly worsened host survival compared to treatment with vehicle or non-P-gp substrates. This effect was seen with cancer chemotherapeutic agents (paclitaxel and vincristine) and with the MDR modulator, trans-flupenthixol. To determine the mechanism(s) underlying this observation, we studied alterations in pharmacokinetics, pharmacodynamics, and metastasis. We found that the drug-induced acceleration of disease was associated with increased metastases. P-gp(+) cells treated with P-gp substrates demonstrated several pro-metastatic features, including membrane ruffling and invasion through a hepatocyte monolayer. These results suggest that the treatment of MDR tumors with P-gp substrates may produce changes in malignant behavior that could adversely affect therapeutic outcomes.

UR - http://www.scopus.com/inward/record.url?scp=0033539901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033539901&partnerID=8YFLogxK

U2 - 10.1006/bbrc.1999.1757

DO - 10.1006/bbrc.1999.1757

M3 - Article

C2 - 10581184

AN - SCOPUS:0033539901

VL - 266

SP - 167

EP - 173

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 1

ER -